BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, declared newly reports financial results for the fiscal quarter finished October 31, 2k19.
3rd-Quarter Financial Results
For the 3rd-financial quarter finished October 31, 2k19, total operating costs were $2.10M, compared with total operating costs of $4.40M in the previous financial year’s 3rd-quarter.
Net loss for the financial quarter finished October 31, 2k19 was $2.10M, or $0.140 for each share, compared with a net loss of $4.40M, or $0.570 for each share, throughout the previous financial year’s 3rd-quarter.
Excluding stock-based compensation cost, non-GAAP net loss for the financial quarter finished October 31, 2k19 was $1.90M, or $0.130 for each share. Throughout the 3rd-quarter of the previous financial year, the comparable non-GAAP net loss was $3.70M, or $0.490 for each share.
Cash and cash equivalents were $1.40M as of October 31, 2k19.